StockNews.com began coverage on shares of Evoke Pharma (NASDAQ:EVOK – Free Report) in a report issued on Sunday. The firm issued a sell rating on the specialty pharmaceutical company’s stock.
Evoke Pharma Stock Performance
NASDAQ:EVOK opened at $6.45 on Friday. The stock has a 50 day moving average price of $4.86 and a 200 day moving average price of $5.52. The stock has a market cap of $55.45 million, a PE ratio of -3.52 and a beta of 0.39. Evoke Pharma has a one year low of $3.54 and a one year high of $17.88.
Evoke Pharma (NASDAQ:EVOK – Get Free Report) last announced its earnings results on Tuesday, August 13th. The specialty pharmaceutical company reported ($0.93) EPS for the quarter, missing analysts’ consensus estimates of ($0.72) by ($0.21). The firm had revenue of $2.55 million for the quarter. Evoke Pharma had a negative net margin of 86.74% and a negative return on equity of 964.25%.
Evoke Pharma Company Profile
Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.
Featured Stories
- Five stocks we like better than Evoke Pharma
- Best Stocks Under $5.00
- Boeing: Why Analysts Think Now’s The Time To Be Brave
- TSX Venture Exchange (Formerly Canadian Venture Exchange)
- Advanced Micro Devices is Building Momentum with AI: Buy the Dip
- Roth IRA Calculator: Calculate Your Potential Returns
- Can Evolv Stock Recover From Its Massive Self-Inflicted Drop?
Receive News & Ratings for Evoke Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
